The recent surge in investments into specialized pharmaceutical companies, particularly those focusing on groundbreaking therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for game-changing treatments and significant returns is undeniable, the linked risks are also signif